Table 2. Operative findings by type of acellular dermal matrix.
| CGCRYODERM (n=32) | DermACELL (n=32) | P value | |
|---|---|---|---|
| Mastectomy indication, n (%) | 0.1317 | ||
| Malignancy | 29 (90.63) | 24 (75.00) | |
| Contralateral risk-reducing surgery | 3 (9.38) | 8 (25.00) | |
| Type of mastectomy, n (%) | 0.8013 | ||
| Skin-sparing mastectomy | 15 (46.88) | 14 (43.75) | |
| Nipple-sparing mastectomy | 16 (50.00) | 17 (53.13) | |
| Modified-radical mastectomy | 1 (3.13) | 1 (3.13) | |
| Axillary surgery, n (%) | 0.6547 | ||
| Sentinel lymph node biopsy | 21 (65.63) | 19 (59.38) | |
| Axillary lymph node dissection | 11 (34.38) | 13 (40.63) | |
| Number of lymph nodes examined (mean ± SD) | 6.42±5.82 | 3.77±5.06 | 0.0770 |
| Timing of reconstruction, n (%) | – | ||
| Immediate | 31 (96.8) | 31 (3.13) | |
| Delayed | 1 (3.13) | 1 (3.13) | |
| Type of reconstruction, n (%) | – | ||
| Two-stage TE/implant | 16 (50.00) | 16 (50.00) | |
| Siltex® textured | 13 (40.63) | 13 (40.63) | |
| Biocell® textured | 3 (9.38) | 3 (9.38) | |
| Direct-to-implant (DTI) | 16 (50.00) | 16 (50.00) | |
| Anatomical textured | 15 (46.88) | 15 (46.88) | |
| Smooth round | 1 (3.13) | 1 (3.13) | |
| ADM surface area, cm2 (mean ± SD) | 90.97±11.37 | 105.75±21.38 | <0.0001* |
| Mastectomy weight, g (mean ± SD) | 372.73±212.33 | 347.79±177.60 | 0.0121* |
| Permanent implant volume, cc (mean ± SD) | 359.00±78.25 | 351.00±85.14 | 0.1680 |
| TE volume, cc (mean ± SD) | 403.13±76.31 | 400.00±81.65 | 1.0000 |
| Initial TE fill (%) (mean ± SD) | 39.98±21.71 | 41.06±22.36 | 0.3750 |
| Expander-to-implant time, d (mean ± SD) | 288.93±122.55 | 288.93±122.55 | – |
*, P value <0.05.